BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 23033007)

  • 21. High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells.
    Hothi P; Martins TJ; Chen L; Deleyrolle L; Yoon JG; Reynolds B; Foltz G
    Oncotarget; 2012 Oct; 3(10):1124-36. PubMed ID: 23165409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppressing glioblastoma stem cell function by aldehyde dehydrogenase inhibition with chloramphenicol or disulfiram as a new treatment adjunct: an hypothesis.
    Kast RE; Belda-Iniesta C
    Curr Stem Cell Res Ther; 2009 Dec; 4(4):314-7. PubMed ID: 19500061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigation of the key chemical structures involved in the anticancer activity of disulfiram in A549 non-small cell lung cancer cell line.
    Butcher K; Kannappan V; Kilari RS; Morris MR; McConville C; Armesilla AL; Wang W
    BMC Cancer; 2018 Jul; 18(1):753. PubMed ID: 30031402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disulfiram/Copper Suppresses Cancer Stem Cell Activity in Differentiated Thyroid Cancer Cells by Inhibiting BMI1 Expression.
    Ni YL; Chien PJ; Hsieh HC; Shen HT; Lee HT; Chen SM; Chang WW
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The disulfiram/copper complex induces apoptosis and inhibits tumour growth in human osteosarcoma by activating the ROS/JNK signalling pathway.
    Guo W; Zhang X; Lin L; Wang H; He E; Wang G; Zhao Q
    J Biochem; 2021 Oct; 170(2):275-287. PubMed ID: 33792698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for the efficacy of disulfiram and copper combination in glioblastoma multiforme - A propos of a case.
    Karamanakos PN; Trafalis DT; Papachristou DJ; Panteli ES; Papavasilopoulou M; Karatzas A; Kardamakis D; Nasioulas G; Marselos M
    J BUON; 2017; 22(5):1227-1232. PubMed ID: 29135106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
    Lun X; Wells JC; Grinshtein N; King JC; Hao X; Dang NH; Wang X; Aman A; Uehling D; Datti A; Wrana JL; Easaw JC; Luchman A; Weiss S; Cairncross JG; Kaplan DR; Robbins SM; Senger DL
    Clin Cancer Res; 2016 Aug; 22(15):3860-75. PubMed ID: 27006494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram.
    Triscott J; Rose Pambid M; Dunn SE
    Stem Cells; 2015 Apr; 33(4):1042-6. PubMed ID: 25588723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disulfiram inhibits TGF-β-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK/NF-κB/Snail pathway.
    Han D; Wu G; Chang C; Zhu F; Xiao Y; Li Q; Zhang T; Zhang L
    Oncotarget; 2015 Dec; 6(38):40907-19. PubMed ID: 26517513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liposome encapsulated Disulfiram inhibits NFκB pathway and targets breast cancer stem cells in vitro and in vivo.
    Liu P; Wang Z; Brown S; Kannappan V; Tawari PE; Jiang W; Irache JM; Tang JZ; Armesilla AL; Darling JL; Tang X; Wang W
    Oncotarget; 2014 Sep; 5(17):7471-85. PubMed ID: 25277186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells.
    Liu X; Wang L; Cui W; Yuan X; Lin L; Cao Q; Wang N; Li Y; Guo W; Zhang X; Wu C; Yang J
    Oncotarget; 2016 Sep; 7(36):58516-58530. PubMed ID: 27542268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic approaches identify a garlic-derived chemical, Z-ajoene, as a glioblastoma multiforme cancer stem cell-specific targeting agent.
    Jung Y; Park H; Zhao HY; Jeon R; Ryu JH; Kim WY
    Mol Cells; 2014 Jul; 37(7):547-53. PubMed ID: 25078449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation.
    Raha D; Wilson TR; Peng J; Peterson D; Yue P; Evangelista M; Wilson C; Merchant M; Settleman J
    Cancer Res; 2014 Jul; 74(13):3579-90. PubMed ID: 24812274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
    Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
    Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
    Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
    Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Juglone induces apoptosis of tumor stem-like cells through ROS-p38 pathway in glioblastoma.
    Wu J; Zhang H; Xu Y; Zhang J; Zhu W; Zhang Y; Chen L; Hua W; Mao Y
    BMC Neurol; 2017 Apr; 17(1):70. PubMed ID: 28388894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disulfiram Sensitizes a Therapeutic-Resistant Glioblastoma to the TGF-β Receptor Inhibitor.
    Liu CC; Wu CL; Lin MX; Sze CI; Gean PW
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Smac mimetic promotes glioblastoma cancer stem-like cell differentiation by activating NF-κB.
    Tchoghandjian A; Jennewein C; Eckhardt I; Momma S; Figarella-Branger D; Fulda S
    Cell Death Differ; 2014 May; 21(5):735-47. PubMed ID: 24488095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disulfiram/copper complex activated JNK/c-jun pathway and sensitized cytotoxicity of doxorubicin in doxorubicin resistant leukemia HL60 cells.
    Xu B; Shi P; Fombon IS; Zhang Y; Huang F; Wang W; Zhou S
    Blood Cells Mol Dis; 2011 Dec; 47(4):264-9. PubMed ID: 21911303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
    Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
    Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.